Case Reports
Early Access
Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Use of upadacitinib in pediatric comorbidities
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 9 January 2026
684
Views
393
Downloads
Authors
We present a case of a 15-year-old male diagnosed with multiple autoimmune conditions, including atopic dermatitis (AD), Crohn’s disease (CD), alopecia areata (AA), and eosinophilic gastroenteropathy. After failure of previous therapies, the patient was successfully treated with upadacitinib, a Janus Kinase 1 (JAK-1) inhibitor. Significant improvement in skin and gastrointestinal symptoms, as well as hair regrowth, was observed following 16 weeks of treatment. This case highlights the therapeutic potential of JAK inhibitors like upadacitinib in managing complex autoimmune disorders that share common pathogenic pathways.
Downloads
Download data is not yet available.
Citations
1. Padda IS, Bhatt R, Patel P, Parmar M. Upadacitinib. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from:
www.ncbi.nlm.nih.gov/books/NBK572088/#:~:text=Mechanism%20of%20Action (accessed on 4 July 2024).
2. Dignass A, Esters P, Flauaus C. Upadacitinib in Crohn’s disease. Expert Opin Pharmacother 2024;25:359-70. DOI: https://doi.org/10.1080/14656566.2024.2333964
3. Novielli D, Foti C, Principi M, et al. Upadacitinib in concurrent Crohn’s disease, atopic dermatitis and alopecia areata: A case report. J Eur Acad Dermatol Venereol 2024;38:e8-10. DOI: https://doi.org/10.1111/jdv.19377
4. Kageyama R, Ito T, Hanai S, et al. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci 2021;22:2618. DOI: https://doi.org/10.3390/ijms22052618
5. Dudek P, Fabisiak A, Zatorski H, et al. Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. J Clin Med 2021;10:5660. DOI: https://doi.org/10.3390/jcm10235660
6. Maghfour J, Olson J, Conic RRZ, Mesinkovska NA. The Association between Alopecia and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Dermatology 2021;237:658-72. DOI: https://doi.org/10.1159/000512747
7. Fu J, Sia T, Solecki R, et al. Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis. J Allergy Clin Immunol Pract 2024;12:1649-51. DOI: https://doi.org/10.1016/j.jaip.2024.02.031
How to Cite
1.
Mortato E, Rao LM, Aloi M, Cioni A, Matteini E, Fico A, et al. Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient: Use of upadacitinib in pediatric comorbidities. Dermatol Reports [Internet]. 2026 Jan. 9 [cited 2026 Jul. 22];. Available from: https://journals.pagepress.net/dr/article/view/10165
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
